Nasonex, Rozerem ads most recalled of 2007

Share this article:
Nasonex ad tops in consumer recall
Nasonex ad tops in consumer recall

DTC TV prescription drug ads featuring an animated bee and a talking beaver were most recalled by consumers during 2007, according to ad performance tracking firm IAG Research.

A 30-second spot featuring Schering-Plough's Nasonex bee was the most recalled broadcast and cable TV ad, followed by a 60-second spot for Takeda's Rozerem featuring the tagline “Your Dreams Miss You.”

Ads for Merck/Schering/Plough's Vytorin and Pfizer's Lipitor featuring Dr. Robert Jarvik followed close behind in terms of consumer ad recall. (See data below).

Most recalled new prescription drug/vaccine ads -- (based on new ads launched in calendar 2007 - 1.1.07 through 12.31.07)

1. Nasonex,Schering-Plough- Animated bee talks about prevention of allergy symptoms, 30- second spot

2. Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at bus stop; "Your Dreams Miss You", 60-second spot

3.Vytorin, Merck/Schering-Plough- Plates of food next to shots of relatives; tuna and peas, Grandma Louise, 60-second spot

4.Lipitor, Pfizer- Dr. Robert Jarvik in white lab coat discusses heart disease, 60-second spot

5.(Tie) Chantix Pfizer- Tortoise and hare, 60-second spot
Vytorin, Merck/Schering-Plough- Plates of food next to shots of realtives; Grandpa Bo, bowtie pasta, 60-second spot

6.(Tie) Lunesta, Sepracor- Luna moth flies into bedrooms, 60-second spot
Cialis Eli Lilly- Couples in various romantic places, 60-second spot

7.(Tie)Gardasil, Merck- Various young women (cowgirl, colorguard, gymnast) Tagline: "One Less," 60-second spot
Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at office; "Your Dreams Miss You," 60-second spot

-courtesy IAG Research

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.